Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 18;9(5):217.
doi: 10.3390/bioengineering9050217.

Application of Sygen® in Diabetic Peripheral Neuropathies-A Review of Biological Interactions

Affiliations
Review

Application of Sygen® in Diabetic Peripheral Neuropathies-A Review of Biological Interactions

Marcelo Amaral Coelho et al. Bioengineering (Basel). .

Abstract

This study investigates the role of Sygen® in diabetic peripheral neuropathy, a severe disease that affects the peripheral nervous system in diabetic individuals. This disorder often impacts the lower limbs, causing significant discomfort and, if left untreated, progresses into more serious conditions involving chronic ulcers and even amputation in many cases. Although there are management strategies available, peripheral neuropathies are difficult to treat as they often present multiple causes, especially due to metabolic dysfunction in diabetic individuals. Gangliosides, however, have long been studied and appreciated for their role in neurological diseases. The monosialotetrahexosylganglioside (GM1) ganglioside, popularly known as Sygen, provides beneficial effects such as enhanced neuritic sprouting, neurotrophism, neuroprotection, anti-apoptosis, and anti-excitotoxic activity, being particularly useful in the treatment of neurological complications that arise from diabetes. This product mimics the roles displayed by neurotrophins, improving neuronal function and immunomodulation by attenuating exacerbated inflammation in neurons. Furthermore, Sygen assists in axonal stabilization and keeps nodal and paranodal regions of myelin fibers organized. This maintains an adequate propagation of action potentials and restores standard peripheral nerve function. Given the multifactorial nature of this complicated disorder, medical practitioners must carefully screen the patient to avoid confusion and misdiagnosis. There are several studies analyzing the role of Sygen in neurological disorders. However, the medical literature still needs more robust investigations such as randomized clinical trials regarding the administration of this compound for diabetic peripheral neuropathies, specifically.

Keywords: diabetic peripheral neuropathy; gangliosides; neuroprotection; regenerative medicine; sygen.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Diabetic peripheral neuropathy.
Figure 2
Figure 2
Sygen mediates neuronal stabilization.

References

    1. Misra U.K., Kalita J., Nair P.P. Diagnostic approach to peripheral neuropathy. Ann. Indian Acad. Neurol. 2008;11:89–97. doi: 10.4103/0972-2327.41875. - DOI - PMC - PubMed
    1. Tesfaye S., Boulton A.J.M., Dyck P.J., Freeman R., Horowitz M., Kempler P., Lauria G., Malik R.A., Spallone V., Vinik A., et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33:2285–2293. doi: 10.2337/dc10-1303. - DOI - PMC - PubMed
    1. Terkelsen A.J., Karlsson P., Lauria G., Freeman R., Finnerup N., Jensen T.S. The diagnostic challenge of small fibre neuropathy: Clinical presentations, evaluations, and causes. Lancet Neurol. 2017;16:934–944. doi: 10.1016/S1474-4422(17)30329-0. - DOI - PubMed
    1. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., Ziegler D. Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962. doi: 10.2337/diacare.28.4.956. - DOI - PubMed
    1. Hicks C.W., Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr. Diabetes Rep. 2019;19:1–86. doi: 10.1007/s11892-019-1212-8. - DOI - PMC - PubMed

LinkOut - more resources